ReviewCNS drugs2009
Armodafinil.
Review in CNS drugs, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 214 citations in OpenAlex.
- Recent Advances and Emerging Pharmacotherapeutic Approaches for Central Hypersomnolence Disorders.Clinical pharmacology : advances and applications · 2026Review
- Central nervous system stimulants in recreational and medical use.CNS spectrums · 2025Review
- Chalcogen bond-guided conformational isomerization enables catalytic dynamic kinetic resolution of sulfoxides.Nature communications · 2022Article
- Pharmacological treatments of fibromyalgia in adults; overview of phase IV clinical trials.Frontiers in pharmacology · 2022Review
- Quantitative determination of armodafinil in human plasma by liquid chromatography-electrospray mass spectrometry: Application to a clinical study.Biomedical chromatography : BMC · 2018Article
- The Novel Modafinil Analog, JJC8-016, as a Potential Cocaine Abuse Pharmacotherapeutic.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017Article
- Hypersomnia in Mood Disorders: a Rapidly Changing Landscape.Current sleep medicine reports · 2015Article
- R-modafinil attenuates nicotine-taking and nicotine-seeking behavior in alcohol-preferring rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015Article
- Monoamine reuptake inhibitors in Parkinson's disease.Parkinson's disease · 2015Review
- Article
- Wake-promoting pharmacotherapy for psychiatric disorders.Current psychiatry reports · 2014Review
- Electroencephalogram effects of armodafinil: comparison with behavioral alertness.Journal of clinical pharmacology · 2013Article
- R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse.Biological psychiatry · 2012Article
- Hypoxia--implications for pharmaceutical developments.Sleep & breathing = Schlaf & Atmung · 2010Review
- Structure-Activity Relationships at the Monoamine Transporters for a Novel Series of Modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) Analogues.ACS medicinal chemistry letters · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Armodafinil is the R-enantiomer of modafinil, a wake-promoting agent, that primarily affects areas of the brain involved in controlling wakefulness. Once-daily armodafinil was effective in improving wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome (OSA) [despite treatment of the underlying condition], narcolepsy or shift work sleep disorder (SWSD) in four large (n > 195), double-blind, multinational trials of 12 weeks' duration. Compared with placebo, mean sleep latency (coprimary endpoint) was significantly improved with armodafinil 150 or 250 mg once daily in patients with OSA or narcolepsy, and with armodafinil 150 mg once daily in patients with SWSD, as assessed by the Multiple Sleep Latency Test (MSLT) or the Maintenance of Wakefulness Test (MWT). Furthermore, a significantly higher proportion of armodafinil than placebo recipients achieved a response (at least a minimal improvement) on the Clinical Global Impressions of Change (CGI-C) scale at study end in these four trials (coprimary endpoint). Once-daily armodafinil was generally well tolerated in adult patients with excessive sleepiness associated with OSA (despite treatment of the underlying condition), narcolepsy or SWSD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.